These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21926165)

  • 1. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.
    Jiang L; Siu MK; Wong OG; Tam KF; Lu X; Lam EW; Ngan HY; Le XF; Wong ES; Monteiro LJ; Chan HY; Cheung AN
    Clin Cancer Res; 2011 Nov; 17(21):6924-33. PubMed ID: 21926165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
    Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
    PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro.
    Du M; Qiu Q; Gruslin A; Gordon J; He M; Chan CC; Li D; Tsang BK
    PLoS One; 2013; 8(1):e54572. PubMed ID: 23359652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-129 targets CDK1 and iASPP to modulate Burkitt lymphoma cell proliferation in a TAp63-dependent manner.
    Zou H; Zou R; Chen K; Zhu C; Tian X; You Y; He X
    J Cell Biochem; 2018 Nov; 119(11):9217-9228. PubMed ID: 30105797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of iASPP correlates with poor prognosis and chemoresistance/radioresistance in FIGO Ib1-IIa squamous cell cervical cancer.
    Cao L; Huang Q; He J; Lu J; Xiong Y
    Cell Tissue Res; 2013 May; 352(2):361-9. PubMed ID: 23420450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
    Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
    Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
    Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
    Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
    Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
    Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
    PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of iASPP Expression Suppresses Proliferation, Invasion and Increases Chemosensitivity to Paclitaxel of Head and Neck Squamous Cell Carcinoma
    Liu ZZ; Kuang WL; Zeng WJ; Xiao JY; Tian YQ
    Chin Med Sci J; 2019 Sep; 34(3):184-193. PubMed ID: 31601301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells.
    Ling YH; Yang Y; Tornos C; Singh B; Perez-Soler R
    Cancer Res; 1998 Aug; 58(16):3633-40. PubMed ID: 9721872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.
    Huang KC; Yang J; Ng MC; Ng SK; Welch WR; Muto MG; Berkowitz RS; Ng SW
    Eur J Cancer; 2016 Nov; 67():152-163. PubMed ID: 27669502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of iASPP in head and neck squamous cell carcinoma and its clinical significance.
    Liu Z; Zhang X; Huang D; Liu Y; Zhang X; Liu L; Li G; Dai Y; Tan H; Xiao J; Tian Y
    Med Oncol; 2012 Dec; 29(5):3381-8. PubMed ID: 22815155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis.
    Liu X; Kang J; Liu F; Wen S; Zeng X; Liu K; Luo Y; Ji X; Zhao S
    Tumour Biol; 2016 May; 37(5):6323-30. PubMed ID: 26628298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
    Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
    Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
    Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.